NEOD001
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
AL Amyloidosis
Conditions
AL Amyloidosis
Trial Timeline
Jun 14, 2017 → May 30, 2018
NCT ID
NCT03154047About NEOD001
NEOD001 is a phase 2 stage product being developed by Prothena for AL Amyloidosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03154047. Target conditions include AL Amyloidosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03154047 | Phase 2 | Terminated |
| NCT02613182 | Phase 2 | Terminated |
| NCT02312206 | Phase 3 | Terminated |
| NCT01707264 | Phase 1/2 | Completed |
Competing Products
20 competing products in AL Amyloidosis